+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Application of a medium-energy collimator for I-131 imaging after ablation treatment of differentiated thyroid cancer



Application of a medium-energy collimator for I-131 imaging after ablation treatment of differentiated thyroid cancer



Annals of Nuclear Medicine 28(6): 551-558



High-energy (HE) collimators are usually applied for I-131 imaging after ablation treatment of differentiated thyroid cancer (DTC). However, purchase of HE collimators has been avoided in many nuclear medicine departments because the HE collimators are more expensive than other collimators. In this study, we compared the I-131 imaging using HE- and medium-energy (ME) collimators, which is more versatile than HE collimators. To simulate DTC patients with extra-thyroid beds, a phantom of acrylic containers containing I-131 was used. To simulate patients with thyroid beds, four phantoms representing extra-thyroid beds were arranged around the phantom representing normal thyroid tissues. Patients administered 1.11 or 3.70 GBq NaI-131 were also evaluated. Whole-body imaging and SPECT imaging of the phantoms and patients performed using HE-general-purpose (HEGP) and ME-low-penetration (MELP) collimators, and full-width at half maximum (FWHM) and percent coefficient of variation (%CV) were measured. In the extra-thyroid beds, FWHM and %CV with MELP were negligibly different from those with HEGP in whole-body imaging. Although FWHM with MELP was a little different from that with HEGP in SPECT imaging, %CV with MELP was significantly higher than that with HEGP. In the thyroid beds, only an extra-thyroid bed including higher radioactivity was identified in whole-body imaging with both collimators. Although SPECT images with MELP could not clarify extra-thyroid beds with low radioactivity, HEGP could identify them. In patients, although some whole-body images with MELP could not detect extra-thyroid beds, whole-body imaging with HEGP and SPECT imaging with both collimators could detect them. Although HEGP is the best collimator for I-131 imaging, MELP is applicable for not only whole-body imaging but also SPECT imaging.

(PDF emailed within 0-6 h: $19.90)

Accession: 051607360

Download citation: RISBibTeXText

PMID: 24710758

DOI: 10.1007/s12149-014-0845-6



Related references

Sentinel node detection in patients with breast cancer: low-energy all-purpose collimator or medium-energy collimator?. Clinical Nuclear Medicine 30(5): 369-370, 2005

Sentinel node detection in patients with breast cancer: low-energy all-purpose collimator or medium-energy collimator?. Clinical Nuclear Medicine 29(10): 609-613, 2004

Usefulness of medium-energy collimator for sentinel node lymphoscintigraphy imaging in breast cancer patients. Journal of Nuclear Medicine Technology 34(3): 153-159, 2006

Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods. Nuclear Medicine Communications 32(9): 840-846, 2011

Advantages of upright position imaging with medium-energy collimator for sentinel node lymphoscintigraphy in breast cancer patients. Annals of Nuclear Medicine 21(2): 123-128, 2007

Prototype imaging protocols for monitoring the efficacy of iodine-131 ablation in differentiated thyroid cancer. Hellenic Journal of Nuclear Medicine 16(3): 175-180, 2014

A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment. Hellenic Journal of Nuclear Medicine 16(2): 103-106, 2013

Rare adverse effect of discontinuation of levothyroxine treatment for 131I ablation of thyroid remnant in a patient with differentiated thyroid cancer. Endocrinologia Y Nutricion 60(7): 412-414, 2014

Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH. Endocrine: -, 2016

Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine-131 in patients with intermediate-risk differentiated thyroid cancer. Nuclear Medicine Communications 38(11): 927-931, 2017

High-Energy Collimator Is Preferable to Medium-Energy Collimator for Evaluating 223Ra Uptake in Bone Metastasis at 2 Weeks Postinjection. Clinical Nuclear Medicine, 2017

Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. Journal of Nuclear Medicine 48(7): 1043-1046, 2007

Presentation and practical management to optimize radioiodine treatment of well differentiated thyroid cancer: ablation of thyroid remnants with radioiodine. Radiobiologia, Radiotherapia 28(5): 707-710, 1987

Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium. European Journal of Nuclear Medicine and Molecular Imaging 37(2): 242-249, 2010

Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment. Cancer Medicine 4(7): 1031-1038, 2016